Cargando…

An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis

BACKGROUND: The Apo-1/Fas (CD95) molecule is an apoptosis-signaling cell surface receptor belonging to the tumor necrosis factor (TNF) receptor family. Both Fas and Fas ligand (FasL) are expressed in activated mature T cells, and prolonged cell activation induces susceptibility to Fas-mediated apopt...

Descripción completa

Detalles Bibliográficos
Autores principales: Niino, Masaaki, Kikuchi, Seiji, Fukazawa, Toshiyuki, Miyagishi, Ryuji, Yabe, Ichiro, Tashiro, Kunio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC122076/
https://www.ncbi.nlm.nih.gov/pubmed/12188927
http://dx.doi.org/10.1186/1471-2377-2-8
_version_ 1782120303932997632
author Niino, Masaaki
Kikuchi, Seiji
Fukazawa, Toshiyuki
Miyagishi, Ryuji
Yabe, Ichiro
Tashiro, Kunio
author_facet Niino, Masaaki
Kikuchi, Seiji
Fukazawa, Toshiyuki
Miyagishi, Ryuji
Yabe, Ichiro
Tashiro, Kunio
author_sort Niino, Masaaki
collection PubMed
description BACKGROUND: The Apo-1/Fas (CD95) molecule is an apoptosis-signaling cell surface receptor belonging to the tumor necrosis factor (TNF) receptor family. Both Fas and Fas ligand (FasL) are expressed in activated mature T cells, and prolonged cell activation induces susceptibility to Fas-mediated apoptosis. The Apo-1/Fas gene is located in a chromosomal region that shows linkage in multiple sclerosis (MS) genome screens, and studies indicate that there is aberrant expression of the Apo-1/Fas molecule in MS. METHODS: Mva I polymorphism on the Apo-1/Fas promoter gene was detected by PCR-RFLP from the DNA of 114 Japanese patients with conventional MS and 121 healthy controls. We investigated the association of the Mva I polymorphism in Japanese MS patients using a case-control association study design. RESULTS: We found no evidence that the polymorphism contributes to susceptibility to MS. Furthermore, there was no association between Apo-1/Fas gene polymorphisms and clinical course (relapsing-remitting course or secondary-progressive course). No significant association was observed between Apo-1/Fas gene polymorphisms and the age at disease onset. CONCLUSIONS: Overall, our findings suggest that Apo-1/Fas promoter gene polymorphisms are not conclusively related to susceptibility to MS or the clinical characteristics of Japanese patients with MS.
format Text
id pubmed-122076
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1220762002-09-09 An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis Niino, Masaaki Kikuchi, Seiji Fukazawa, Toshiyuki Miyagishi, Ryuji Yabe, Ichiro Tashiro, Kunio BMC Neurol Research Article BACKGROUND: The Apo-1/Fas (CD95) molecule is an apoptosis-signaling cell surface receptor belonging to the tumor necrosis factor (TNF) receptor family. Both Fas and Fas ligand (FasL) are expressed in activated mature T cells, and prolonged cell activation induces susceptibility to Fas-mediated apoptosis. The Apo-1/Fas gene is located in a chromosomal region that shows linkage in multiple sclerosis (MS) genome screens, and studies indicate that there is aberrant expression of the Apo-1/Fas molecule in MS. METHODS: Mva I polymorphism on the Apo-1/Fas promoter gene was detected by PCR-RFLP from the DNA of 114 Japanese patients with conventional MS and 121 healthy controls. We investigated the association of the Mva I polymorphism in Japanese MS patients using a case-control association study design. RESULTS: We found no evidence that the polymorphism contributes to susceptibility to MS. Furthermore, there was no association between Apo-1/Fas gene polymorphisms and clinical course (relapsing-remitting course or secondary-progressive course). No significant association was observed between Apo-1/Fas gene polymorphisms and the age at disease onset. CONCLUSIONS: Overall, our findings suggest that Apo-1/Fas promoter gene polymorphisms are not conclusively related to susceptibility to MS or the clinical characteristics of Japanese patients with MS. BioMed Central 2002-08-21 /pmc/articles/PMC122076/ /pubmed/12188927 http://dx.doi.org/10.1186/1471-2377-2-8 Text en Copyright © 2002 Niino et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Niino, Masaaki
Kikuchi, Seiji
Fukazawa, Toshiyuki
Miyagishi, Ryuji
Yabe, Ichiro
Tashiro, Kunio
An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis
title An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis
title_full An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis
title_fullStr An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis
title_full_unstemmed An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis
title_short An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis
title_sort examination of the apo-1/fas promoter mva i polymorphism in japanese patients with multiple sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC122076/
https://www.ncbi.nlm.nih.gov/pubmed/12188927
http://dx.doi.org/10.1186/1471-2377-2-8
work_keys_str_mv AT niinomasaaki anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT kikuchiseiji anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT fukazawatoshiyuki anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT miyagishiryuji anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT yabeichiro anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT tashirokunio anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT niinomasaaki examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT kikuchiseiji examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT fukazawatoshiyuki examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT miyagishiryuji examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT yabeichiro examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis
AT tashirokunio examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis